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early childhood, and the frequency and characteristics of adult-
onset disease remain controversial.
Objective: We sought to determine the proportion of subjects
who report atopic eczema symptoms between birth and
midadulthood and to examine demographic, immunologic, and
genetic factors associated with period of symptom onset.
Methods: We conducted a longitudinal study using data from 2
nationally representative community-based birth cohorts from
the United Kingdom: the British Cohort Studies 1958 and 1970.
Subjects were followed from birth through age 42 to 50 years.
The primary outcome was the age period of self-reported atopic
eczema symptom onset based on repeated measures of self-
reported atopic eczema at each survey wave.
Results: The annual period prevalence of atopic eczema ranged
from 5% to 15% in 2 cohorts of more than 17,000 participants
each followed from birth through middle age. There was no
clear trend in prevalence by age, and among adults reporting
active atopic eczema during a given year, only 38% had
symptom onset reported in childhood. When compared with
subjects whose eczema started in childhood, those with adult-
onset disease were more likely to be women, from Scotland or
Northern England, of lower childhood socioeconomic group,
smokers in adulthood, and less likely to have a history of
asthma. In a subanalysis using data from the 1958 cohort only,
genetic mutations previously associated with atopic eczema,
including filaggrin-null mutations, and allergen-specific IgE
were more common among those with childhood-onset disease.
Conclusion: Rates of self-reported atopic eczema remain high
after childhood, and adult-onset atopic eczema has different risk
factor associations than childhood-onset eczema. (J Allergy Clin
Immunol 2019;144:710-9.)
Key words: Atopic eczema, atopic dermatitis, natural history,
epidemiology
Atopic eczema (also known as atopic dermatitis or just eczema)
is the leading cause of skin-related disability,1 but most epidemi-
ologic research has focused only on incidence early in life or pat-
terns of disease in childhood.2 Recent data suggest that atopic
eczema is also common among adults, but whether these trends
are due to increasing persistence of disease or new-onset disease
later in life is unclear.3-5 Atopic eczema is known towax andwane
over time, yet there are limited longitudinal data on patterns of
disease activity over the life course. Cross-sectional studies
have reported proportions of adult-onset atopic eczema ranging
from 13% to 60%.6-15 The validity of these estimates have been
questioned because of the potential for recall bias (adults might
not accurately recall whether they had eczema as children) or
the possibility that disease expression in adulthood is due to
migration from low- to high-prevalence climates.16 In addition,
studies of dermatology clinic populations suggest that there might
be important genetic and phenotypic differences in patients with
adult-onset disease, but these might not be representative of the
general population and are controversial for the reasons stated
above. Data from population-based longitudinal birth cohorts
are needed to understand the patterns and predictors of atopic
eczema presentation across the life course.
It is important to understand the epidemiology of adult-onset
atopic eczema for a number of reasons. First, because mostdiagnostic criteria specify that disease begins early in childhood,
patients and providers might feel uncertain of the diagnosis in
adults with new-onset disease. Although additional testing is
often appropriate to rule out differential diagnoses,17 if many
adults do not meet the diagnostic criteria developed for children,
they might be subject to anxiety about the lack of a clear diag-
nosis, excessive testing, and limited access to new treatment
options.18
Second, if risk factors for adult-onset atopic eczema differ, this
raises the possibility of a different subtype of atopic eczema and
could help to elucidate differences in disease pathophysiology
and drivers of disease activity.
Finally, understanding whether childhood-onset and adult-
onset atopic eczema differ is important for refining preventative
and treatment strategies. The latter is particularly timely because
many new small molecules and biologic agents are currently
under development and clinical testing for use in patients with
atopic eczema.18
Using 2 large cohorts followed from birth for 4 to 5 decades that
are representative of the general United Kingdom (UK) popula-
tion, we sought to determine the proportion of patients with
symptoms of self-reported atopic eczema in childhood and
adulthood and examine factors associated with period of onset.METHODS
We performed a longitudinal cohort study using data from the 1958 and
1970 British Cohort Studies (BCS1958 and BCS70), which are ongoing
multidisciplinary studies that include 17,196 and 17,415 babies born in Great
Britain during one week in March 1958 and March 1970, respectively.19,20
There have been 8 to 9 subsequent waves of follow-up in each cohort at
approximately 5- to 10-year intervals (Fig 1). In the 1958 study, waves at
ages 33, 46, and 55 years did not include data on atopic eczema and thus
were not included in the analysis. Additional information on response patterns
in both cohorts has been reported elsewhere.21,22Outcomes
The primary outcome was parent-reported or self-reported period
prevalence of atopic eczema based on a standardized question asking
about ‘‘eczema’’ during or before the past year or since the last survey at
each wave of follow-up (see Table E1 in this article’s Online Repository at
www.jacionline.org). In descriptive analyses this measure coincided well
with standardized clinical examinations among children in the 1958 birth
cohort,23,24 and a similar question has been shown to have high sensitivity
and specificity for physician-diagnosed atopic eczema in US children and
adults.25 We categorized subjects who reported atopic eczema into 2
groups: those whose first report of atopic eczema occurred in childhood
(positive parental report during or before the last year at age 5-7 and/or
10-11 years) and those with adult-onset atopic eczema (first report of atopic
eczema at age >_23 years). For the primary analysis, we did not include
atopic eczema data from age 16 years because it is considered a transitional
period between pediatric and adult care in the UK and the 1958 cohort only
asked about annual period prevalence (rather than period and lifetime
FIG 1. Flow chart of ages at which atopic eczema activity was assessed.
Percentages represent the proportion of the original sample assessed at
each age. Red shading indicates ages used to define childhood-onset atopic
eczema, and blue shading indicates ages used to define adult-onset atopic
eczema. Data from age 16 years were included with childhood-onset
disease in a sensitivity analysis.
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included.Covariates
Additional covariates were chosen based on prior literature showing an
association with atopic eczema.23,26,27 These included sex, ethnic group, his-
tory of any breast-feeding, region of residence in childhood, region of resi-
dence in adulthood (at age 42 years), childhood smoke exposure (either
parent reporting current smoking during childhood surveys), smoking in adult-
hood (personal report of current smoking on any of the surveys in adulthood),
household size (categorized into <_3 persons and >_4 persons), in utero smoke
exposure (mother reported any smoking during pregnancy), birth weight,
and the Registrar General’s designation of social class (a standard measure
based on the father’s highest occupational status reported on any survey at
ages 0-10/11 years for childhood and a subject’s own occupation at ages 23-
50 years for adulthood). Personal history of asthma or allergic rhinitis/hay fe-
ver was based on questions repeated at multiple ages (see Table E2 in this ar-
ticle’s Online Repository at www.jacionline.org). Data on parental history of
asthma and hay feverwere only available in the 1970 cohort andwere based on
either parent’s report of either condition at age 5 years.Primary analysis
In both cohorts we estimated the cumulative lifetime prevalence and age-
specific period prevalence. We also calculated the proportion of subjectswith childhood-onset versus adult-onset disease among those who reported
active atopic eczema in adulthood. We used multivariable logistic regression
to test for differences in demographic and risk factors between (1)
childhood-onset and no atopic eczema, (2) adult-onset and no atopic
eczema, and (3) childhood-onset and adult-onset atopic eczema. After
examining the regression results for consistency in each cohort separately,
we conducted a meta-analysis of individual participant data, assuming fixed
effects across studies to account for the clustering of participants within
cohorts.28Subgroup analysis and biospecimen data
At the age of 44 to 45 years, 5974 subjects in the 1958 cohort were followed
up with a biomedical examination and blood sampling.29 For the subgroup of
the 1958 cohort who had biospecimen data available, we repeated regressions
including variables for the presence of any filaggrin (FLG)–null mutation and
a non-FLG genetic risk score, total IgE level, and allergen-specific IgE level
modeled as 3-level categorical variables derived as tertiles. The total concen-
tration of serum IgE antibodies and the presence of specific IgE to house dust
mite, mixed grass pollen, and cat fur were ascertained by using the HYTEC
enzyme immunoassay (HYCOR Biomedical, Garden Grove, Calif), with a
detection threshold of 0.35 kU/L.30 Four common null mutations of the
FLG gene that have been associated with risk of atopic dermatitis in European
populations31,32 were genotyped directly by LGC Genomics (Berlin, Ger-
many) using KASP genotyping technology. FLG-null status was defined as
the presence of 1 or more risk variants of rs61816761 (R501X),
rs150597413 (S3247X), rs558269137 (2282del4), or rs138726443
(R2447X, formerly rs386430951). An additional 29 variants outside the
FLG region were selected for inclusion in a polygenic risk score based on pre-
viously published associations with atopic dermatitis (please see the Methods
section in this article’s Online Repository at www.jacionline.org for additional
description of the methods used and a full list of references). A non-FLG ge-
netic risk scorewas generated as the sum of imputed allele dosages for the risk-
associated variant at each of these single nucleotide polymorphisms.Sensitivity analyses
For the primary analysis, we did not include atopic eczema data from age
16 years, as described above. In a preplanned sensitivity analysis we tested the
effect of this decision on our results by including subjects who reported atopic
eczema during the past year at age 16 years with the childhood-onset group.
We also examined the potential for misclassification bias by restricting the
sample to those who reported having seen a physician for their eczema in the
past year and had no history of self-reported psoriasis or contact dermatitis.Missing data
We explored patterns of missing data throughout follow-up. For the
primary analysis, we included only subjects with at least 1 survey response in
childhood and 1 survey response in adulthood (Fig 1). Additionally, to explore
the effect of missing data, we performed multiple imputation in each cohort
separately with iterative chained equations to impute missing exposure,
outcome, and covariate data. Thirty imputed data sets were generated, and
average results from repeated analyses were compared with the complete
case analysis. All statistical analyses were conducted with Stata software
(version 14; StataCorp, College Station, Tex).RESULTS
At birth, 17,196 subjects were recruited into the 1970 cohort,
and 17,415 subjects were recruited into the 1958 cohort. There
were intermittent missing data and attrition in both cohorts over
time; 56% to 57% of the original birth sample responded to the
last wave of follow-up (Fig 1). Data on atopic eczema in both
childhood and adulthood were available for 11,886 members of
TABLE I. Patient characteristics by AE and period of onset
1970 cohort 1958 cohort
No AE
(n 5 8,611)
Any AE (n 5 3,275 [28% of cohort])
No AE
(n 5 10,825)
Any AE (n 5 2,318 [18% of cohort])
Childhood onset
(n 5 1,972 [60% of
those with AE])
Adult onset
(n 5 1,303 [40% of
those with AE])
Childhood onset
(n 5 1,313 [57%
of those with AE])
Adult onset
(n 5 1,005 [43%
of those with AE])
No. (%) No. (%)
Sex
Male 4,406 (51.2) 996 (50.5) 467 (35.8) 5,594 (51.7) 663 (50.5) 383 (38.1)
Female 4,205 (48.8) 976 (49.5) 836 (64.2) 5,231 (48.3) 650 (49.5) 622 (61.9)
Ethnicity
European, white 7,164 (96.3) 1,709 (96.8) 1,071 (96.5) 8,749 (99.0) 1,147 (98.7) 822 (98.9)
Other 272 (3.7) 56 (3.2) 39 (3.5) 88 (1.0) 15 (1.3) 9 (1.1)
Region of residence in
childhood
Southern England 2,552 (33.4) 725 (40.3) 418 (36.5) 3,193 (29.5) 431 (32.8) 311 (30.9)
Central England 2,112 (27.6) 487 (27.0) 316 (27.6) 3,224 (29.8) 433 (33.0) 303 (30.1)
Northern England 2,988 (39.0) 589 (32.7) 411 (35.9) 4,408 (40.7) 449 (34.2) 391 (38.9)
Region of residence at
age 42 y
Southern England 2,283 (37.0) 636 (43.3) 402 (38.5) 3,136 (37.1) 429 (40.5) 365 (39.9)
Central England 1,671 (27.1) 404 (27.5) 290 (27.8) 2,199 (26.0) 302 (28.5) 261 (28.5)
Northern England 2,215 (35.9) 429 (29.2) 351 (33.7) 3,115 (36.9) 327 (30.9) 289 (31.6)
Social class in childhood
I/II 3,049 (35.4) 891 (45.2) 489 (37.6) 3,072 (28.5) 455 (34.7) 306 (30.5)
IIIa/b 4,905 (57.0) 974 (49.4) 719 (55.2) 6,597 (61.2) 749 (57.1) 603 (60.2)
IV/V 648 (7.5) 106 (5.4) 94 (7.2) 1,104 (10.2) 107 (8.2) 93 (9.3)
Social class in adulthood
I/II 4,326 (53.2) 1,156 (61.1) 720 (57.4) 4,573 (43.7) 607 (47.6) 482 (49.6)
IIIa/b 3,003 (36.9) 612 (32.3) 454 (36.2) 4,671 (44.7) 536 (42.1) 402 (41.4)
IV/V 801 (9.9) 125 (6.6) 80 (6.4) 1212 (11.6) 131 (10.3) 87 (9.0)
Household size
<_3 Persons 821 (10.7) 183 (10.1) 121 (10.6) 857 (8.9) 115 (9.3) 75 (8.4)
>_4 Persons 6,845 (89.3) 1,626 (89.9) 1,022 (89.4) 8,766 (91.1) 1,119 (90.7) 821 (91.6)
Smoking during
pregnancy
No 4,635 (54.1) 1,155 (58.8) 730 (56.2) 7,096 (66.3) 910 (70.3) 669 (67.6)
Any 3,934 (45.9) 809 (41.2) 570 (43.8) 3,600 (33.7) 384 (29.7) 320 (32.4)
Childhood smoke
exposure
No 2,616 (34.2) 691 (38.2) 396 (34.7) 2,173 (27.2) 316 (31.9) 215 (28.4)
Any 5,025 (65.8) 1,117 (61.8) 745 (65.3) 5,805 (72.8) 675 (68.1) 541 (71.6)
Adult smoking
No 4,647 (54.1) 1,095 (55.6) 649 (49.8) 6,076 (56.2) 764 (58.3) 533 (53.0)
Any 3,950 (45.9) 875 (44.4) 654 (50.2) 4,736 (43.8) 547 (41.7) 472 (47.0)
Atopy
History of asthma 1,451 (16.9) 627 (31.8) 378 (29.0) 2,362 (21.8) 485 (36.9) 322 (32.0)
History of allergic
rhinitis/hay fever
3,160 (36.7) 1,090 (55.3) 684 (52.5) 3,070 (28.4) 648 (49.4) 416 (41.4)
Parental history of
atopy
1,563 (22.3) 660 (39.3) 281 (27.1) — — —
Birth weight (kg), mean
(SD)
3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.4 (0.5) 3.3 (0.5)
Breast-feeding
No 4,851 (63.7) 1,020 (56.9) 687 (60.5) 3,193 (32.2) 338 (26.9) 283 (30.9)
Any 2,766 (36.3) 773 (43.1) 449 (39.5) 6,729 (67.8) 920 (73.1) 634 (69.1)
FLG-null mutations*
No — — — 3,689 (90.3) 446 (79.1) 337 (86.9)
Any — — — 398 (9.7) 118 (20.9) 51 (13.1)
Non-FLG SNPs*
<25 Risk alleles — — — 1,196 (29.3) 124 (22.0) 97 (25.0)
25-28 Risk alleles — — — 1,536 (37.6) 189 (33.5) 139 (35.8)
>28 Risk alleles — — — 1,355 (33.2) 251 (44.5) 152 (39.2)
Total IgE*
<30 kU/L — — — 2,157 (52.8) 239 (42.4) 184 (47.4)
30-99 kU/L — — — 1,154 (28.2) 176 (31.2) 119 (30.7)
>_100 kU/L — — — 776 (19.0) 149 (26.4) 85 (21.9)
(Continued)
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TABLE I. (Continued)
1970 cohort 1958 cohort
No AE
(n 5 8,611)
Any AE (n 5 3,275 [28% of cohort])
No AE
(n 5 10,825)
Any AE (n 5 2,318 [18% of cohort])
Childhood onset
(n 5 1,972 [60% of
those with AE])
Adult onset
(n 5 1,303 [40% of
those with AE])
Childhood onset
(n 5 1,313 [57%
of those with AE])
Adult onset
(n 5 1,005 [43%
of those with AE])
No. (%) No. (%)
Allergen-specific IgE*
<0.35 kU/L — — — 3,007 (73.6) 321 (56.9) 260 (67.0)
0.35-3.5 kU/L — — — 369 (9.0) 51 (9.0) 37 (9.5)
AE, Atopic eczema; SNP, single nucleotide polymorphism.
*Data were only available for a subset of the 1958 cohort (n 5 5,039).
FIG 2. Atopic eczema (AE) period prevalence and cumulative lifetime prevalence by age and cohort. *Prev-
alence from age 0 to 5 years for the 1970 cohort and age 0 to 7 years for the 1958 cohort. Bars represent 95%
CIs.
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graphic characteristics and missing covariate data are shown in
Table I and Table E3 in this article’s Online Repository at
www.jacionline.org.
Consistent with international trends, atopic eczema was more
common in the 1970 cohort: the cumulative lifetime prevalence
of atopic eczema was 28% in the 1970 cohort and 18% in the
1958 cohort. Among those with atopic eczema at any time point,
40% and 43% reported disease for the first time in adulthood in
the 1970 and 1958 cohorts, respectively. The period prevalence
of atopic eczema ranged from 7% to 14% during any given
period in childhood and 5% to 12% during any given period in
adulthood (see Table E1), and there was no clear trend acrossages in either cohort (Fig 2). Among those who reported atopic
eczema activity at each survey wave in adulthood, the majority
(mean, 62%) did not have a report of eczema during childhood
(Fig 3).
The strength of association from multivariate regression
models comparing subjects with childhood-onset atopic eczema
and adult-onset atopic eczema with subjects without atopic
eczema differed, as is evidenced by the results of the regression
model directly comparing those with adult-onset disease with
those with childhood-onset disease (Table II). We found that sub-
jects with adult-onset atopic eczema were more likely to be
women, to be from Northern geographic areas in the UK, to
have been of lower social class in childhood, and to have been
FIG 3. Proportion of subjects with symptom onset in adulthood among
those with active atopic eczema (AE) at each survey wave in adulthood.
Note: Age periods marked by asterisks are from the 1958 cohort; the
remainder are from the 1970 cohort. Childhood-onset disease was defined
as first report at age 0 to 11 years, and adult-onset disease was defined as
first report after age 22 to 23 years.
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asthma (Table II).
In a subgroup analysis using data from 3365 subjects in the
1958 cohort who were part of the biomedical follow up at age 44
to 45 years and had atopic eczema, genetic, IgE, and covariate
data available, we examined rates of known risk alleles for AD
and both total IgE and allergen-specific IgE levels. We found that
21% of those with childhood-onset disease, 13% with adult-onset
disease, and 10% without any history of atopic eczema had at
least 1 FLG-null mutation (Table I). Both childhood-onset and
adult-onset atopic eczema were associated with FLG-null muta-
tions, but the association was stronger for childhood-onset than
adult-onset atopic eczema in multivariable analyses (odds ratio
[OR], 2.73 [95% CI, 2.06-3.63] and 1.49 [95% CI, 1.01-2.19],
respectively; Table III). A high non-FLG genetic risk score pre-
dicted childhood-onset atopic eczema, but there was little evi-
dence for an association between the non-FLG genetic risk
score and adult-onset disease (OR, 1.81 [95% CI, 1.37-2.40]
and 1.18 [95% CI, 0.85-1.64], respectively; Table III). Similarly,
a high allergen-specific IgE levels predicted childhood-onset
atopic eczema, but there was little evidence for an association be-
tween the allergen-specific IgE and adult-onset disease (OR, 1.90
[95% CI, 1.32-2.74] and 0.86 [95% CI, 0.54-1.36], respectively;
Table III).
Analyses after multiple imputation to address missing data
showed similar results (see Table E4 in this article’s Online Re-
pository at www.jacionline.org). In a sensitivity analysis using
data from age 16 years, we found that an additional 260 subjects
would be classified as having childhood-onset disease in the 1970
cohort as would an additional 193 children in the 1958 cohort.
The overall proportion with childhood-onset disease remained
near 60% in both cohorts, and results of regression analyses did
not substantiatively change (see Table E5 in this article’s Online
Repository at www.jacionline.org). Finally, when we excluded
patients with a history of contact dermatitis or psoriasis, and re-
spondents who did not report seeing a physician in the past year
for their atopic eczema (see Table E6 in this article’s Online Re-
pository at www.jacionline.org), we again found similar results
(see Table E7 in this article’s Online Repository at www.
jacionline.org).DISCUSSION
Using 2 large population-based cohorts followed from birth
into midlife, we found the period prevalence of self-reported
atopic eczema was 5% to 14%. One of the defining characteristics
of childhood atopic eczema is early age at onset; however, the
majority of those reporting symptoms in adulthood did not have
disease onset in childhood. When comparing those with
childhood-onset and adult-onset atopic eczema, we found
differences in demographic characteristics, atopic comorbidities,
IgE profiles in adulthood, and genetic risk factors. Our findings
help to address the gap in knowledge about the epidemiology
of adult atopic eczema and suggest that there might be
different subtypes of adult disease that warrant additional
characterization.Strengths and limitations
Our study is unique in that there is prospective follow-up of
subjects residing in the UK from birth through middle age. The
data come from 2 large community-based cohorts broadly
representative of the UK general population. Consistent with
previous reports and international trends,33-35 we found that the
overall prevalence of atopic eczema increased between 1958
and 1970, but there did not appear to be a difference in trends
across calendar years (see Fig E1 in this article’s Online Reposi-
tory at www.jacionline.org). Two population-based mail surveys
in the United States and Italy also found high rates of adult-onset
disease (54% and 60% of the population respectively)6,7 but have
been questioned because of the possibility for poor recall of child-
hood disease or migration to new climates.16 These biases are un-
likely to affect our estimates because subjects in our cohorts were
born in the UK and followedwith repeated assessments from birth
through midlife.
We likely found a lower proportion of subjects with early-onset
disease because our data included a longer duration of prospective
follow-up than prior studies.36 For example, an older study using
data available through age 23 years from the 1958 BCS concluded
that of the 870 cases by the age of 16 years, 66% had age of onset
by the age of 7 years.37 By comparison, using the same initial
data, now with extended follow-up through age 50 years, we
found only 41% had onset of symptoms by age 7 years.
Longitudinal studies of asthma have similarly found higher rates
of late-onset and recurrent disease with longer periods of
follow-up.38,39
A limitation of our study is that our outcome of atopic eczema
was based on parental report or self-report, and it is likely that
some patients were misclassified. Misclassification could include
other forms of eczema, including stasis dermatitis and irritant
contact dermatitis in adults. Nearly all of the population-based
epidemiologic literature on atopic eczema has relied on self-
reported assessment of disease, and prior studies have shown that
self-report performs reasonably well: in a multicenter US study
with a physician’s diagnosis as the gold standard, the positive
predictive value of self-report was 0.87 (95% CI, 0.78-0.96) in
children and 0.76 (95% CI, 0.64-0.85) in adults.25 Of note, it per-
formed better for children than adults, and the study was conduct-
ed with dermatology clinic patients in whom the prevalence of
atopic eczema was greater than in the general population, mean-
ing the estimates could be slightly inflated. Additional analyses to
examine the potential for misclassification, including restricting
our sample to thosewho reported having seen a physician for their
TABLE II. Multivariable regression results (complete case analysis)
OR (95% CI)
P value
Childhood-onset vs no
AE (n 5 17,373)
Adult-onset vs no
AE (n 5 12,956)
Adult-onset vs childhood-onset
AE (n 5 12,956)
Sex
Male Reference Reference Reference
Female 1.04 (0.95-1.13) 1.75 (1.56-1.98) 1.66 (1.44-1.92) <.001
Ethnicity
European, white Reference Reference Reference
Other 0.86 (0.65-1.15) 1.07 (0.73-1.57) 1.23 (0.77-1.97) .391
Region of early childhood residence
Southern England Reference Reference Reference
Central England/Wales 0.91 (0.82-1.02) 0.88 (0.73-1.08) 0.95 (0.75-1.20) .651
Northern England/Scotland 0.77 (0.70-0.86) 1.03 (0.83-1.29) 1.31 (1.01-1.71) .045
Region of residence at age 42 y
Southern England — Reference Reference
Central England/Wales — 1.17 (0.96-1.42) 1.14 (0.90-1.43) .281
Northern England/Scotland — 0.87 (0.70-1.09) 0.92 (0.71-1.20) .551
Highest social class in childhood*
I/II Reference Reference Reference
III 0.80 (0.73-0.88) 1.00 (0.88-1.14) 1.23 (1.05-1.43) .009
IV/V 0.70 (0.58-0.85) 0.99 (0.77-1.26) 1.38 (1.01-1.89) .044
Highest social class in adulthood*
I/II — Reference Reference
III — 0.92 (0.81-1.04) 1.00 (0.86-1.17) .956
IV/V — 0.75 (0.58-0.96) 0.90 (0.66-1.22) .489
Household size in early childhood
<_3 Persons Reference Reference Reference
>_4 Persons 1.01 (0.87-1.17) 1.08 (0.88-1.31) 1.10 (0.87-1.40) .439
In utero smoke exposure
No Reference Reference Reference
Any 0.93 (0.84-1.03) 0.94 (0.82-1.07) 0.99 (0.84-1.16) .915
Childhood smoke exposure
No Reference Reference Reference
Any 0.93 (0.85-1.03) 1.02 (0.89-1.16) 1.07 (0.91-1.26) .400
Adult smoking
No — Reference Reference
Any — 1.26 (1.13-1.42) 1.20 (1.04-1.38) .013
Asthma
No Reference Reference Reference
Any 1.85 (1.68-2.04) 1.45 (1.27-1.66) 0.79 (0.68-0.93) .004
Allergic rhinitis/hay fever
No Reference Reference Reference
Any 1.81 (1.65-1.98) 1.59 (1.41-1.80) 0.90 (0.77-1.04) .141
Birth weight
Per kilogram increase 1.09 (1.00-1.19) 1.01 (0.90-1.13) 0.90 (0.79-1.04) .156
Breast-feeding
No Reference Reference Reference
Any 1.18 (1.07-1.29) 1.11 (0.98-1.26) 0.94 (0.81-1.09) .411
Boldface indicates P < .05.
AE, Atopic eczema.
*Registrar General’s social class: I, professional; II, managerial and technical; III, skilled; IV, partly skilled; and V, unskilled.
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sis, were similar to primary regression results (see Table E7).
Although these results do not rule out the potential for misclassi-
fication bias, they suggest that the magnitude of bias is likely to be
small. Furthermore, as described in more detail below, our find-
ings on FLG mutations, IgE levels, and demographic factors are
similar to smaller studies of clinical populations with
physician-diagnosed atopic eczema.15,16,40,41
An additional limitation of our study is that surveys were
fielded at multiyear intervals, and we cannot rule out the
possibility that atopic eczema might be underreported. Forexample, some parents might not recall a history of early or
mild atopic eczema when asked at age 5 to 7 years of their child’s
life; however, the recall is likely to be superior to that on surveys
of adults asked about their own early childhood disease decades
later.42 Similarly, many of the adult surveys only asked about
atopic eczema during the past year (as shown in Table E1), and
therefore our results might underestimate adult-onset atopic
eczema. Detailed phenotypic assessments of participants to detect
atopic eczema at frequent intervals would be desirable, but they
are impractical in large population-based cohorts followed for
more than 40 years.
TABLE III. Multivariable regression results from subanalysis with genetic data from the 1958 birth cohort*
OR (95% CI)
P value
Child-onset vs
no AE (n 5 3444)
Adult-onset vs
no AE (n 5 3365)
Adult-onset vs
child-onset AE (n 5 3365)
FLG-null mutations
No Reference Reference Reference
Any 2.73 (2.06-3.63) 1.49 (1.01-2.19) 0.54 (0.35-0.83) .006
Non-FLG SNPs
<25 Risk alleles Reference Reference Reference
25-28 Risk alleles 1.17 (0.87-1.58) 1.07 (0.77-1.48) 0.87 (0.57-1.32) .507
>28 Risk alleles 1.81 (1.37-2.40) 1.18 (0.85-1.64) 0.64 (0.43-0.97) .036
Total IgE
<30 kU/L Reference Reference Reference
30-99 kU/L 1.14 (0.83-1.56) 1.08 (0.76-1.54) 0.96 (0.61-1.51) .866
>_100 kU/L 0.93 (0.63-1.38) 1.08 (0.68-1.71) 1.22 (0.68-2.17) .503
Allergen-specific IgE
<0.35 kU/L Reference Reference Reference
0.35-3.5 kU/L 1.09 (0.69-1.71) 1.05 (0.63-1.74) 0.94 (0.49-1.78) .846
>_3.5 kU/L 1.90 (1.32-2.74) 0.86 (0.54-1.36) 0.44 (0.25-0.77) .004
Sex
Male Reference Reference Reference
Female 0.98 (0.79-1.22) 1.67 (1.27-2.19) 1.71 (1.23-2.39) .002
Region of early childhood residence
Southern England Reference Reference Reference
Central England/Wales 0.84 (0.64-1.10) 1.03 (0.68-1.57) 1.17 (0.71-1.94) .535
Northern England/Scotland 0.65 (0.49-0.85) 1.30 (0.81-2.07) 1.64 (0.92-2.93) .094
Region of residence at age 42 y
Southern England — Reference Reference
Central England/Wales — 1.15 (0.77-1.70) 1.16 (0.72-1.87) .550
Northern England/Scotland — 0.67 (0.42-1.08) 0.85 (0.47-1.53) .585
Social class in childhood
I/II Reference Reference Reference
IIIa/b 0.99 (0.78-1.25) 1.05 (0.78-1.41) 1.08 (0.76-1.55) .662
IV/V 0.79 (0.50-1.26) 1.29 (0.79-2.09) 1.61 (0.85-3.06) .142
Highest social class in adulthood
I/II — Reference Reference
III — 0.85 (0.64-1.13) 0.77 (0.54-1.08) .131
IV/V — 0.74 (0.44-1.22) 0.75 (0.40-1.41) .369
Household size in early childhood
<_3 Persons Reference Reference Reference
>_4 Persons 0.87 (0.59-1.27) 1.14 (0.69-1.89) 1.30 (0.71-2.38) .388
In utero smoke exposure
No Reference Reference Reference
Any 0.92 (0.71-1.19) 0.99 (0.73-1.35) 1.08 (0.74-1.58) .697
Childhood smoke exposure
No Reference Reference Reference
Any 0.93 (0.73-1.19) 0.93 (0.69-1.26) 0.98 (0.68-1.42) .910
Adult smoking
No — Reference Reference
Any — 1.01 (0.77-1.33) 0.94 (0.68-1.32) .739
Asthma
No Reference Reference Reference
Any 1.53 (1.21-1.94) 1.38 (1.03-1.85) 0.88 (0.62-1.25) .482
Allergic rhinitis/hay fever
No Reference Reference Reference
Any 1.62 (1.26-2.07) 1.54 (1.14-2.06) 0.95 (0.66-1.36) .761
Birth weight
Per kilogram increase 0.98 (0.79-1.21) 1.03 (0.80-1.34) 1.03 (0.75-1.41) .870
Breast-feeding
No Reference Reference Reference
Any 1.18 (0.91-1.51) 0.97 (0.73-1.30) 0.81 (0.57-1.17) .264
Boldface indicates P < .05
AE, Atopic eczema; SNP, single nucleotide polymorphism.
*Does not include data from survey at age 50 years.
Registrar General’s social class: I, professional; II, managerial and technical; III, skilled; IV, partly skilled; and V, unskilled.
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attrition over time. Prior research has shown that in the 1970
cohort there is a weak predictive effect of sex and socioeconomic
status on response: men from lower social backgrounds with less
educated parents are less likely to respond, which has previously
been described in detail.43 Because the cohort was not explicitly
designed to study atopic disease, it is unlikely that attrition was
differential by atopic eczema status. Nonetheless, to address
missing data issues, we performed multiple imputation and found
results that were consistent with those of the complete case
analysis.Implications for research and clinical practice
Our results highlight the need for additional research to better
characterize adult eczema and understand whether pathophysi-
ology differs by age of onset. Atopic eczema is known to have a
multifactorial cause, and we found genetic, immunologic, de-
mographic, and risk factor differences between those with
childhood-onset and those with adult-onset disease. Only a few
other smaller studies have explicitly addressed age-associated
differences in patients with atopic eczema, and their findings are
largely consistent with our results. Studies from dermatology
clinic populations in Germany and the United States also found
that those with self-reported adult-onset disease were more likely
to be female41 and less likely to have a personal or family history
of atopic disease,40,41 increased IgE levels,40,44 or FLG muta-
tions45,46 but did not find differences by smoking or socioeco-
nomic status.41 In contrast, a small case-control study from
Taiwan found both current and ever smoking were strong inde-
pendent risk factors for adult-onset disease,47 and a recent
meta-analysis found high rates of smoking in adults with AD
overall but did not differentiate by age of onset.48
Atopic eczema is considered a clinical diagnosis, and the most
widely used diagnostic criteria (the Hanifin and Rajka criteria, the
UK Working Party criteria refinement of the Hanifin and Rajka
criteria, and the American Academy of Dermatology criteria) all
include early age at onset and history of atopy.49 Clinicians eval-
uating adults with a potential diagnosis of atopic eczema should
recognize that the majority of patients might not have symptom
onset in childhood. Moreover, although subjects with adult-
onset disease have a greater probability of having a history of
other atopic disease than subjects without atopic eczema, asthma
was only present in about one third and allergic rhinitis in about
one half of patients with atopic eczema in our study (Table I).
Diagnostic criteria were developed based on expert opinion
among dermatologists whose clinical experience might not reflect
the distribution of disease in the general population, and none
have been validated in a population-based study of adults.50
Our data highlight the need to better understand what is adult
‘‘atopic’’ eczema and to refine diagnostic criteria for use in the
general adult population. In the meantime, clinical trials of adult
atopic eczema should describe the method by which physicians
made the diagnosis (if any) and whether validated diagnostic
criteria were used to permit exploration of study heterogeneity
and enable subgroup analysis in future meta-analyses.Terminology
We choose to use the term atopic eczema based on a call for
consistency in the literature.51 There are regional variations interminology; in the United Kingdom the term eczema is consid-
ered more precise than dermatitis, whereas in the United States
the term atopic dermatitis is usually preferred.51 In either case
use of the term atopic has been debated because, even among chil-
dren, not all disease is associated with increased IgE levels or co-
morbid atopic conditions, including asthma or rhinitis. Indeed,
previous research has suggested that the majority of what is called
atopic eczema is not atopic at a population level.52 Our findings
that adult-onset disease was associated with lower rates of IgE
and asthma further call into question the use of the term atopic
in adult disease; nonetheless, we have continued to use this termi-
nology for consistency and clarity. Future studies might uncover
subtypes of adult-onset disease that require new terminology.Conclusion
We found that self-reported adult-onset atopic eczema is
common among 2 community-based British cohorts. Differences
in genetic, demographic, and immunologic profiles between those
with childhood-onset and those with adult-onset disease suggest
there might be different subtypes of atopic eczema and emphasize
the need for better characterization of adult-onset disease and
validation of diagnostic tools in this population. These data are
particularly timely because dozens of new treatments are under
development and clinical testing for AD,18 and trial populations
selected on the basis of early-onset disease are unlikely to be
representative of the general population of adults.
We thank the participants in the British Longitudinal Cohort Studies, the
Centre for Longitudinal Studies (CLS), the UCL Institute of Education for use
of these data, and the UK Data Service for making them available. However,
neither CLS nor theUKData Service bear any responsibility for the analysis or
interpretation of these data. We are also incredibly grateful for patient input
from Amanda Roberts, Nathan Jetter, John Lupiano, and Wendy Smith
Begolka on behalf of the National Eczema Association.
Clinical implications: Adult-onset eczema is common andmight
be less likely to present with other atopic disease.
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